Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Outterson K, et al. Among authors: aurigemma r. Nat Rev Drug Discov. 2016 Sep;15(9):589-590. doi: 10.1038/nrd.2016.155. Epub 2016 Jul 29. Nat Rev Drug Discov. 2016. PMID: 27469032
Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.
Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, Currie BJ, Dance D, Gee JE, Larsen J, Limmathurotsakul D, Morrow MG, Norton R, O'Mara E, Peacock SJ, Pesik N, Rogers LP, Schweizer HP, Steinmetz I, Tan G, Tan P, Wiersinga WJ, Wuthiekanun V, Smith TL. Lipsitz R, et al. Among authors: aurigemma r. Emerg Infect Dis. 2012 Dec;18(12):e2. doi: 10.3201/eid1812.120638. Emerg Infect Dis. 2012. PMID: 23171644 Free PMC article.
Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
Fogli LK, Aurigemma R, Sommers CL, Singh A, Bourcier K, Ernstoff MS; NCI Cell Therapy Workshop Committee. Fogli LK, et al. Among authors: aurigemma r. J Immunother Cancer. 2021 Jul;9(7):e003048. doi: 10.1136/jitc-2021-003048. J Immunother Cancer. 2021. PMID: 34266886 Free PMC article.
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, Alvarez RD. Kim KH, et al. Among authors: aurigemma r. Gynecol Oncol. 2013 Sep;130(3):518-24. doi: 10.1016/j.ygyno.2013.06.003. Epub 2013 Jun 10. Gynecol Oncol. 2013. PMID: 23756180 Free PMC article. Clinical Trial.
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer.
Kim KH, Dmitriev I, O'Malley JP, Wang M, Saddekni S, You Z, Preuss MA, Harris RD, Aurigemma R, Siegal GP, Zinn KR, Curiel DT, Alvarez RD. Kim KH, et al. Among authors: aurigemma r. Clin Cancer Res. 2012 Jun 15;18(12):3440-51. doi: 10.1158/1078-0432.CCR-11-2852. Epub 2012 Apr 17. Clin Cancer Res. 2012. PMID: 22510347 Free PMC article. Clinical Trial.
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
Kim KH, Ryan MJ, Estep JE, Miniard BM, Rudge TL, Peggins JO, Broadt TL, Wang M, Preuss MA, Siegal GP, Hemminki A, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. Kim KH, et al. Among authors: aurigemma r. Hum Gene Ther. 2011 Jul;22(7):821-8. doi: 10.1089/hum.2010.180. Epub 2011 Mar 23. Hum Gene Ther. 2011. PMID: 21171861 Free PMC article.
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.
Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. Kimball KJ, et al. Among authors: aurigemma r. Clin Cancer Res. 2010 Nov 1;16(21):5277-87. doi: 10.1158/1078-0432.CCR-10-0791. Epub 2010 Oct 26. Clin Cancer Res. 2010. PMID: 20978148 Free PMC article. Clinical Trial.
Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.
Matthews K, Noker PE, Tian B, Grimes SD, Fulton R, Schweikart K, Harris R, Aurigemma R, Wang M, Barnes MN, Siegal GP, Hemminki A, Zinn K, Curiel DT, Alvarez RD. Matthews K, et al. Among authors: aurigemma r. Clin Cancer Res. 2009 Jun 15;15(12):4131-7. doi: 10.1158/1078-0432.CCR-08-3354. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509153
Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T, Polley-Nelson J, Noker PE, Wang M, Makhija S, Aurigemma R, Curiel DT, Alvarez RD. Page JG, et al. Among authors: aurigemma r. Am J Obstet Gynecol. 2007 Apr;196(4):389.e1-9; discussion 389.e9-10. doi: 10.1016/j.ajog.2006.12.016. Am J Obstet Gynecol. 2007. PMID: 17403430
20 results